Reviewer’s report

Title: Transgenically-expressed secretoglobin 3A2 accelerates resolution of bleomycin-induced pulmonary fibrosis in mice

Version: 1 Date: 2 January 2015

Reviewer: Julie Ledford

Reviewer’s report:

Major comments:
This is a report by Cai et al examining how transgenically-expressed secretoglobin 3A2 (SCGB3A2) accelerates resolution of pulmonary fibrosis in mice using the bleomycin-model. This is an interesting study as SCGB3A2 has been shown previously to have anti-fibrotic activities. Their research shows that transgenic mice express SCGB3A2 protein approximately 5 fold higher than WT mice and interestingly, while the transgenic mice had exacerbated fibrosis 3 weeks post challenge, they more rapidly resolved inflammation by 6 weeks when compared to WT mice. Overall, this is a wonderful investigation using a novel mouse that furthers our understanding of SCGB3A2 and provides a need to explore its potential as a therapeutic for IPF.

Minor comments:
1. please describe where SCGB3A2 antibody is from (line 162).
2. Lines 204-205 grammar should be corrected to be something more like this “….using methods previously described (ref).”
3. The section starting at line 362 is very long and should be divided up into smaller paragraphs.
4. wording in lines 387-388 is awkward and should be adjusted.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests.